GlaxoSmithKline, Novartis and Astellas are among the investors to have celebrated an exit after cancer therapy developer Bicycle secured $60.7m in its initial public offering.

Bicycle Therapeutics, a UK-based developer of treatments for diseases with a high unmet need backed by corporates Novartis, GlaxoSmithKline and Astellas, floated on the Nasdaq Global Market yesterday in a $60.7m initial public offering. The company issued approximately 4.3 million American Depositary Shares, equivalent to the same number of ordinary shares, priced at $14.00 each,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.